Rifapentine

利福喷丁

Report date: 2023/02/23 20:00:33
NME

Base Information

Drug NameRifapentine
Drug Alias Namerifapentine环戊哌嗪利福霉素利福喷汀rifapentinarifapentinum +[12] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionDNA-directed RNA polymerase beta chain inhibitors
TargetsDNA-directed RNA polymerase beta chain
Therapy Area/IndicationsTuberculosis, PulmonaryTuberculosis, SpinalTuberculosis
Global Approved IndicationsTuberculosis, PulmonaryTuberculosis
Approved Indications in ChinaTuberculosis, Pulmonary
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesShandong UniversitySanofi-Aventis U.S. LlcNational Taiwan University +[4] 
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsTuberculosis, PulmonaryTuberculosis, SpinalTuberculosis
Inactive IndicationsN/A

Other Information

ATC CodeJ04AB05
Related LinksWikipediaDrugBankKEGG